Prognostic Significance of the PC10 Index for Patients with Stage II and III Oesophageal Cancer Treated with Radiotherapy

References

• Katlic MR, Wilkins EW, Grillo HC. Three decades of treat-ment of esophageal carcinoma at the Massachusetts General Hospital. J Thorac Cardiovasc Surg 1990; 99: 929–38.
   Google Scholar
• Earlam R, Cunha-Melo JR. Oesophageal squamous car-cinoma: II. A critical review of radiotherapy. Br J Surg 1980; 67: 457–61.
   Google Scholar
• Ajani JA. Therapy of carcinoma of the oesophagus: either attempt it not or succeed. Eur J Cancer 1995; 31: 790–3.
   Google Scholar
• Wang DY, Xiang YY, Tanaka M, et al. High prevalence of p53 protein overexpression in patients with esophageal cancer in Linxian, China and its relationship to progression and prognosis. Cancer 1994; 74: 3089–96.
   PubMedGoogle Scholar
• Sarbia M, Porschen R, Borchard F, Horstmann O, Willers R, Gabbert HE. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 1994; 74: 2218–23.
   PubMedGoogle Scholar
• Minu AR, Endo M, Sunagawa M. Role of DNA ploidy patterns in esophageal squamous cell carcinoma. Cancer 1994; 74: 578–85.
   Google Scholar
• Yoshida K, Morinaga S, Shimosato Y, Hayata Y. A cell kinetic study of pulmonary adenocarcinoma by an im-munoperoxidase procedure after bromodeoxyuridine labeling. Cancer 1989; 64: 2284–91.
   PubMedGoogle Scholar
• Mama A, Massimo C, Reppetto L, et al. Thymidine labeling index as prognostic factor in resected non-small cell lung cancer. Eur J Cancer 1990; 26: 622–5.
   PubMedGoogle Scholar
• Sahin AA, Ro J, Ro JY, et al. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Cancer 1991; 68: 539–57.
   Google Scholar
• Tateishi M, Ishida T, Mitsudomi T, Sugimachi K. DNA polymerase-a as a putative early relapse marker in non-small cell lung cancer. Cancer 1991; 68: 925–9.
   PubMedGoogle Scholar
• Robins BA, Vega D, Ogata K, Tan EM, Nakamura RM. Immunohistochemical detection of proliferating cell nuclear antigen in solid human malignancies. Arch Pathol Lab Med 1987; 111: 841–5.
   Google Scholar
• Celis JE, Celis A. Cell cycle dependent variations in the distribution of the nuclear protein cyclin/proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc Natl Acad Sci USA 1985; 82: 3262–6.
   PubMed Web of Science ®Google Scholar
• Bravo R, Frank R, Blundell PA, Mcdonald-Bravo H. Cyclin/ PCNA is the auxiliary protein of DNA polymerase-ö. Nature 1987; 326: 515–7.
   Google Scholar
• Yu CCW, Filipe MI. Update on proliferation-associated anti-bodies applicable to formalin fixed paraffin embedded tissue and their clinical applications. Histochem J 1993; 25: 843–53.
   PubMedGoogle Scholar
• Hall PA, Levison DA, Woods At, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sec-tions: an index of cell proliferation with evidence of deregu-lated expression in some neoplasms. J Pathol 1990; 162: 285–94.
   PubMed Web of Science ®Google Scholar
• Jain S, Filipe MI, Hall PA, Wassem N, Lane DP, Levinson DA. Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Pathol 1991; 44: 655–9.
   PubMed Web of Science ®Google Scholar
• Al-Sheneber IF, Shibata HR, Sampalis J, Jothy S. Prognostic significance of proliferating cell nuclear antigen expression in colorectal cancer. Cancer 1993; 71: 1954–9.
   Google Scholar
• Willett CG, Warland G, Cheek R, et al. Proliferating cell nuclear antigen and mitotic activity in rectal cancer: predictor of response to preoperative irradiation. J Clin Oncol 1994; 12: 679–82.
   PubMed Web of Science ®Google Scholar
• Morisaki Y, Shima S, Yoshizumi Y, Sugiura Y, Tanaka S, Tamai S. PCNA immunostaining combined with AgNOR staining in esophageal squamous cell carcinoma to identify patients with a poor prognosis. Surg Today 1995; 25: 389–95.
   PubMedGoogle Scholar
• Kuwano H, Sumiyoshi K, Nozoe T, Yasuda M, Watanabe M, Sugimachi K. Prognostic significance of the Cytophoto-metric DNA content and its relationship with the argyrophilic nucleolar organiser regions (AgNOR) and proliferating cell nuclear antigen (PCNA) in oesophageal cancer. Eur J Surg Oncol 1995; 21: 368–73.
   PubMedGoogle Scholar
• Hickey K, Grehan D, Reid IM, O'Briain S, Walsh TN, Hennessy TP. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer 1994; 74: 1693–8.
   Google Scholar
• Hermanek P, Sobin LH. UICC International Union Against Cancer. TNM classification of malignant tumors. 4th ed. Berlin: Springer-Verlag, 1987: 40–2.
   Google Scholar
• Hareyama M, Nishio M, Kagami Y, Narimatsu N, Saito A, Sakurai T. Intracavitary brachytherapy combined with exter-nal-beam irradiation for squamous cell carcinoma of the thoracic esophagus. Int J Radiat Oncol Biol Phys 1992; 24: 235–40.
   PubMedGoogle Scholar
• Kaplan EL, Meier P. Non-parametric estimation from incom-plete observations. J Am Stat Assoc 1958; 53: 457–81.
   Web of Science ®Google Scholar
• Cox DR. Regression models and life-tables. J Roy Stat Soc B 1972; 34: 187–220.
   Web of Science ®Google Scholar
• Youssef EM, Matsuda T, Takada M, et al. Prognostic signifi-cance of the MIB-1 proliferation index for patients with squamous cell carcinoma of the esophagus. Cancer 1995; 76: 358–66.
   PubMed Web of Science ®Google Scholar
• Girinsky T, Auperin A, Maesiglia H, et al. Accelerated frac-tionation in esophageal cancers: a multivariate analysis on 88 patients. Int .1- Radiat Oncol Biol Phys 1997; 38: 1013–8.
   PubMedGoogle Scholar
• Ozawa S, Ueda M, Ando N, Shimizu N, Abe O. Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer 1989; 63: 2169–73.
   Google Scholar
• Morita M, Kuwano H, Matsuda H, Moriguchi S, Sugimachi K. Prognostic significance of argyrophilic nucleolar organizer regions in esophageal carcinoma. Cancer Res 1991; 51: 5339–41.
   Google Scholar
• Kitagawa Y, Ueda M, Ando N, Shinozawa Y, Shimizu N, Abe O. Significance of int-2/hst-1 coamplification as a prog-nostic factor in patients with esophageal squamous car-cinoma. Cancer Res 1991; 51: 1504–8.
   PubMed Web of Science ®Google Scholar
• Wenz F, Lohr F, Flentje M, Rudat V, Dietz A, Wannen-macher M. Predictive value of the flow cytometric PCNA assay (proliferating cell nuclear antigen) in head and neck tumors after Accelerated-hyperfractionated ra-diochemotherapy. Int .1- Radiat Oncol Biol Phys 1997; 37: 771 — 6.
   Google Scholar
• Nishimura Y, Ono K, Tsutsui K, et al. Esophageal cancer treated with radiotherapy: impact of total treatment time and fractionation. Int .1- Radiat Oncol Biol Phys 1994; 30: 1099–105.
   PubMed Web of Science ®Google Scholar